Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Devimistat - Cornerstone Pharmaceuticals Inc

Drug Profile

Devimistat - Cornerstone Pharmaceuticals Inc

Alternative Names: 6,8-bis(benzylthio)octanoic-acid; Bylantra; CPI-613; ONO-7912

Latest Information Update: 07 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornerstone Pharmaceuticals; Stony Brook University
  • Developer Case Comprehensive Cancer Center; Cornerstone Pharmaceuticals Inc; National Cancer Institute (USA); Ono Pharmaceutical; University of Michigan; Wake Forest University Health Sciences; Wake Forest University School of Medicine
  • Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Sulfides
  • Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Burkitt's lymphoma; Biliary cancer; Acute myeloid leukaemia; Soft tissue sarcoma; Pancreatic cancer; Peripheral T-cell lymphoma; T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II B-cell lymphoma; Burkitt's lymphoma; Small cell lung cancer; Solid tumours; T-cell lymphoma
  • Phase I/II Biliary cancer; Cancer; Clear cell sarcoma; Colorectal cancer
  • Phase I Hodgkin's disease
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 28 Aug 2023 Cornerstone Pharmaceuticals withdraws the phase I trial for Colorectal cancer (Combination therapy, Metastatic- disease, Second-line therapy or greater) (IV, Infusion), prior to enrolment due to no funding (NCT05070104)
  • 16 May 2023 Cornerstone Pharmaceuticals plans a phase II trial for Acute myeloid leukemia (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion) (NCT05854966)
  • 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cholangiocarcinoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top